Treats hypertension. ANDA 77686, held by Actavis Labs Fl Inc. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 77686 (Diltiazem Hydrochloride), held by Actavis Labs Fl Inc, was first approved by FDA on Mar 15, 2010, with 5 approved supplements and 0 published complete response letters.
Matzim LA (diltiazem hydrochloride) extended-release tablets are a nondihydropyridine calcium channel blocker indicated for: treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It can be used alone or in combination with other antihypertensives. improving exercise tolerance in patients with chronic stable angina. 1.1 Hypertension Matzim LA (diltiazem hydrochloride) extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 15, 2010 | Original application | Approved | None posted |
| Diltiazem Hydrochloride420MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride360MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride300MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride120MG · tablet, extended release;oral | Diltiazem Hydrochloride | Rx |
| Apr 9, 2026 | Supplement 23Labeling · Standard review | Approved | None posted |
| Aug 13, 2024 | Supplement 19Labeling · Standard review | Approved | None posted |
| Jul 16, 2024 | Supplement 11Labeling · Standard review | Approved | None posted |
| Nov 8, 2016 | Supplement 10Labeling · Standard review | Approved | None posted |
| Apr 21, 2011 | Supplement 5Labeling | Approved | None posted |
| Mar 15, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters